LEGN
Same story, fresh stamp
Barclays analyst Etzer Darout didn’t exactly rip up the script here — he kept Legend Biotech on a Buy rating and left the $80 price target untouched. In analyst-land, that’s basically a “nothing to see here, still like the setup” kind of move.
Why you should care
For a stock like Legend Biotech, these calls matter because they can help shape sentiment, especially when the name is already trading on expectations around its cell therapy business. A maintained Buy doesn’t bring a fireworks show, but it does tell you the bull case hasn’t been downgraded.
The fine print
- Analyst Etzer Darout was the one holding the line.
- Barclays kept its target at $80.
- TipRanks says Darout has a 55.7% success rate and a 27.2% average return over the past year, which is respectable enough to make the note worth a glance.
Big picture: this is less “new catalyst” and more “the Street still likes the movie.” Investors probably won’t get whiplash from this one, but it keeps Legend Biotech in the favorable camp.